BRIEF-Valeant announces price changes for neurology, GI, urology portfolis
Oct 14 (Reuters) - Valeant Pharmaceuticals International Inc :
* Valeant Patient Access and Pricing Committee comments on recent pricing action decisions
* Patient Access and Pricing Committee has made decisions regarding price changes of products in company's neurology, GI and urology portfolios
* Planned wholesale acquisition price changes, effective October 14, range from 2.0 percent to 9.0 percent
* There will be no pricing adjustments this year on dermatology and ophthalmology products
* 2016 pricing actions across its U.S. branded RX portfolio, represent an increase of less than 2.0 percent within calendar 2016 year Source text for Eikon: Further company coverage:
© Thomson Reuters 2017 All rights reserved.